NASDAQ:SYRS - Syros Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $17.00
Forecasted Upside: 234.65 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
0 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$5.08 As of 05/10/2021 03:21 PM ET

▼ -0.12 (-2.31%)

1 month | 3 months | 12 months

Get New Syros Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SYRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYRS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$17.00

▲ +234.65% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Syros Pharmaceuticals in the last 3 months. The average price target is $17.00, with a high forecast of $20.00 and a low forecast of $13.00. The average price target represents a 234.65% upside from the last price of $5.08.

Buy

The current consensus among 7 polled investment analysts is to buy stock in Syros Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/17/2019

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/15/2020

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/15/2020

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/13/2020

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/11/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/9/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/10/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/10/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/5/2021	Alliance Global Partners	Lower Price Target		$18.00 ➝ $14.00	Low	i
11/10/2020	Brookline Capital Management	Initiated Coverage	Buy	$19.00	Low	i Rating by L. Cann at Brookline Capital Management
11/6/2020	Oppenheimer	Initiated Coverage	Buy	$13.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/4/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$11.00 ➝ $15.00	High	i Rating by A. Fein at HC Wainwright
10/26/2020	Roth Capital	Boost Price Target	Buy	$17.00 ➝ $20.00	High	i
10/25/2020	Oppenheimer	Initiated Coverage	Buy	$13.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
9/22/2020	Alliance Global Partners	Initiated Coverage	Buy	$18.00	Medium	i
8/10/2020	HC Wainwright	Reiterated Rating	Hold	$11.00	Medium	i
8/7/2020	Piper Sandler	Boost Price Target		$14.00 ➝ $18.00	Medium	i
8/6/2020	JMP Securities	Boost Price Target	Outperform	$16.00 ➝ $20.00	Low	i
6/1/2020	Oppenheimer	Initiated Coverage	Buy	$11.00	Medium	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/29/2020	Piper Sandler	Boost Price Target	Overweight	$12.00 ➝ $14.00	Low	i
5/8/2020	HC Wainwright	Reiterated Rating	Hold		High	i
5/7/2020	Oppenheimer	Reiterated Rating	Buy	$11.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/6/2020	HC Wainwright	Reiterated Rating	Neutral	$10.00 ➝ $8.00	High	i Rating by Andrew Fein at HC Wainwright
3/5/2020	Cowen	Reiterated Rating	Buy		High	i
1/17/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$9.00	High	i Rating by D. Nierengarten at Wedbush
12/18/2019	Cowen	Reiterated Rating	Buy		High	i
11/13/2019	HC Wainwright	Reiterated Rating	Hold	$10.00	High	i Rating by Andrew Fein at HC Wainwright
11/12/2019	Cowen	Reiterated Rating	Buy		High	i
10/24/2019	Cowen	Reiterated Rating	Buy		Low	i
10/18/2019	HC Wainwright	Set Price Target	Hold	$10.00	High	i Rating by Andrew Fein at HC Wainwright
10/18/2019	JMP Securities	Lower Price Target	Market Outperform	$18.00 ➝ $16.00	Medium	i
10/17/2019	Piper Jaffray Companies	Lower Price Target		$24.00 ➝ $18.00	High	i
7/12/2019	Roth Capital	Initiated Coverage	Buy	$17.00	High	i Rating by Zegbeh Jallah at Roth Capital
5/2/2019	HC Wainwright	Reiterated Rating	Neutral		Low	i Rating by A. Fein at HC Wainwright
4/25/2019	Wedbush	Reiterated Rating	Outperform	$13.00	Low	i
4/10/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$28.00 ➝ $24.00	Low	i
3/8/2019	Roth Capital	Set Price Target	Buy	$14.00	High	i Rating by Jotin Marango at Roth Capital
3/8/2019	JMP Securities	Reiterated Rating	Mkt Outperform ➝ Mkt Outperform	$18.00	High	i Rating by Konstantinos Aprilakis at JMP Securities
3/8/2019	HC Wainwright	Reiterated Rating	Hold	$10.00	High	i
3/7/2019	Oppenheimer	Set Price Target	Buy	$13.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/14/2019	Oppenheimer	Reiterated Rating	Outperform	$13.00 ➝ $13.00	Low	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/3/2018	Wedbush	Reiterated Rating	Outperform	$13.00	High	i
12/2/2018	Roth Capital	Set Price Target	Buy	$14.00	High	i Rating by Jotin Marango at Roth Capital
11/15/2018	Roth Capital	Set Price Target	Buy	$12.00	Low	i Rating by Jotin Marango at Roth Capital
11/13/2018	Oppenheimer	Set Price Target	Buy	$26.00	Low	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/5/2018	Roth Capital	Upgrade	Neutral ➝ Buy	$12.00	Medium	i Rating by Jotin Marango at Roth Capital
11/1/2018	JMP Securities	Set Price Target	Buy	$33.00	High	i Rating by Konstantinos Aprilakis at JMP Securities
11/1/2018	Oppenheimer	Set Price Target	Buy	$26.00	Low	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
8/8/2018	HC Wainwright	Reiterated Rating	Hold	$10.00	Low	i Rating by A. Fein at HC Wainwright
7/17/2018	Cowen	Reiterated Rating	Buy		Medium	i
3/14/2018	HC Wainwright	Reiterated Rating	Hold	$10.00	High	i Rating by A. Fein at HC Wainwright
3/13/2018	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00	High	i
1/8/2018	Oppenheimer	Set Price Target	Buy	$28.00	High	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/21/2017	HC Wainwright	Reiterated Rating	Hold	$10.00	Low	i
12/13/2017	Oppenheimer	Set Price Target	Buy	$28.00	Medium	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/11/2017	Cowen	Reiterated Rating	Buy		High	i
12/7/2017	Oppenheimer	Reiterated Rating	Buy	$28.00	Low	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
10/31/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$30.00	N/A	i
10/23/2017	Roth Capital	Initiated Coverage	Neutral ➝ Neutral	$15.00	N/A	i Rating by J. Marango at Roth Capital
9/28/2017	JMP Securities	Upgrade	Market Perform ➝ Outperform	$33.00	High	i
8/10/2017	Wedbush	Reiterated Rating	Outperform	$25.00 ➝ $22.84	Medium	i
8/10/2017	JMP Securities	Downgrade	Outperform ➝ Market Perform		Medium	i
8/9/2017	Cowen	Reiterated Rating	Buy		High	i
6/12/2017	Oppenheimer	Set Price Target	Buy	$28.00	High	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
5/16/2017	Wedbush	Reiterated Rating	Outperform	$22.00	High	i
4/12/2017	Oppenheimer	Reiterated Rating	Outperform	$28.00	Low	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
3/20/2017	Wedbush	Reiterated Rating	Outperform	$22.00 ➝ $18.00	High	i
2/27/2017	Oppenheimer	Set Price Target	Buy	$28.00	N/A	i Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/15/2016	Oppenheimer	Reiterated Rating	Buy	$28.00	N/A	i
11/29/2016	Oppenheimer	Initiated Coverage	Outperform	$28.00	N/A	i
11/14/2016	Piper Jaffray Companies	Set Price Target	Buy	$20.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
11/14/2016	Wedbush	Reiterated Rating	Outperform	$18.00	N/A	i
9/22/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$20.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
9/9/2016	HC Wainwright	Reiterated Rating	Hold	$10.00	N/A	i Rating by Andrew Fein at HC Wainwright
7/25/2016	Cowen	Initiated Coverage	Outperform		N/A	i
7/25/2016	JMP Securities	Initiated Coverage	Outperform	$22.00	N/A	i
7/25/2016	Wedbush	Initiated Coverage	Outperform	$18.00	N/A	i Rating by D. Nierengarten at Wedbush
7/25/2016	Piper Jaffray Companies	Initiated Coverage	Overweight	$20.00	N/A	i
7/18/2016	HC Wainwright	Initiated Coverage	Neutral	$10.00	N/A	i Rating by A. Fein at HC Wainwright

(Data available from 5/10/2016 forward)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $5.08

$4.88

$5.25

50 Day Range

MA: $6.99

$5.48

$9.41

52 Week Range

Now: $5.08

$5.07

$15.65

Volume

41,625 shs

Average Volume

733,979 shs

Market Capitalization

$314.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Syros Pharmaceuticals?

The following sell-side analysts have issued research reports on Syros Pharmaceuticals in the last twelve months: Alliance Global Partners, Brookline Capital Management, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for SYRS.

What is the current price target for Syros Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for Syros Pharmaceuticals in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 228.8%. JMP Securities has the highest price target set, predicting SYRS will reach $20.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $13.00 for Syros Pharmaceuticals in the next year.
View the latest price targets for SYRS.

What is the current consensus analyst rating for Syros Pharmaceuticals?

Syros Pharmaceuticals currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYRS will outperform the market and that investors should add to their positions of Syros Pharmaceuticals.
View the latest ratings for SYRS.

What other companies compete with Syros Pharmaceuticals?

Other companies that are similar to Syros Pharmaceuticals include Protagonist Therapeutics, COMPASS Pathways, Keros Therapeutics, Ocular Therapeutix, Avid Bioservices, Shattuck Labs, Repare Therapeutics, Travere Therapeutics, Northwest Biotherapeutics, Aclaris Therapeutics, Stoke Therapeutics, Innoviva, Pliant Therapeutics, Humanigen and Dynavax Technologies.

How do I contact Syros Pharmaceuticals' investor relations team?

Syros Pharmaceuticals' physical mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company's listed phone number is 617-744-1340 and its investor relations email address is [email protected] The official website for Syros Pharmaceuticals is www.syros.com.